Sam Brusco, Associate Editor03.27.23
Digital health company NeuroRPM has gained U.S. Food and Drug Administration (FDA) clearance for its breakthrough NeuroRPM product, which uses artificial intelligence (AI) and the Apple Watch to continuously and passively monitor bradykinesia, tremor, and dyskinesia, the primary symptoms of Parkinson’s disease.
According to the company, the product has the most advanced and comprehensive monitoring capabilities for Parkinson’s available on a wearable device so the full range of symptoms can be tracked day-to-day.
"The clearance of NeuroRPM is a major milestone in the fight against Parkinson's disease," co-founder Dr. Alexander Ksendzovsky, also the Director of Functional Neurosurgery at the University of Maryland, told the press. "This technology will allow for unprecedented insights into the symptoms of Parkinson's disease including bradykinesia, tremor, and dyskinesia, using critical health and wellness data from Apple Watch. NeuroRPM is able to assess even slight changes with accuracy comparable to that of a neurologist. This changes the game for the treatment of Parkinson’s patients.
NeuroRPM consists of proprietary algorithms integrated into an Apple Watch app that collects data passively through the user’s everyday use. NeuroRPM is available by prescription only, and only uses data from Apple Watch that users have chosen to share with the app.
"We are thrilled to be on the new frontier of digital health with NeuroRPM. By leveraging the power of Apple Watch, we are transforming the way individuals with Parkinson's disease understand their health, enabling care providers to make more informed clinical decisions which will lead to better health outcomes. We are honored to help drive this revolution in healthcare," said NeuroRPM president Atila Omer.
According to the company, the product has the most advanced and comprehensive monitoring capabilities for Parkinson’s available on a wearable device so the full range of symptoms can be tracked day-to-day.
"The clearance of NeuroRPM is a major milestone in the fight against Parkinson's disease," co-founder Dr. Alexander Ksendzovsky, also the Director of Functional Neurosurgery at the University of Maryland, told the press. "This technology will allow for unprecedented insights into the symptoms of Parkinson's disease including bradykinesia, tremor, and dyskinesia, using critical health and wellness data from Apple Watch. NeuroRPM is able to assess even slight changes with accuracy comparable to that of a neurologist. This changes the game for the treatment of Parkinson’s patients.
NeuroRPM consists of proprietary algorithms integrated into an Apple Watch app that collects data passively through the user’s everyday use. NeuroRPM is available by prescription only, and only uses data from Apple Watch that users have chosen to share with the app.
"We are thrilled to be on the new frontier of digital health with NeuroRPM. By leveraging the power of Apple Watch, we are transforming the way individuals with Parkinson's disease understand their health, enabling care providers to make more informed clinical decisions which will lead to better health outcomes. We are honored to help drive this revolution in healthcare," said NeuroRPM president Atila Omer.